pharma · Hypophosphatasia · Paroxysmal Nocturnal Hemoglobinuria
Alexion Europe SAS
Alexion Europe SAS clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- EU
- Employees
- 89
- Programs
- 33
- Drugs
- 40
- Patents
- 0
Alexion Europe SAS projects
8 ClinicalTrials.gov programs sponsored by Alexion Europe SAS.
Alexion Europe SAS has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ALXN 2040, Placebo matching ALXN2040
Alexion Europe SAS
Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)
1 trial -
ALXN 2050, ALXN2050 Placebo Tablets
Alexion Europe SAS
Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
1 trial -
ALXN1210-NEPH-202
Alexion Europe SAS
Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
1 trial -
ALXN2350-DCM-201
Alexion Europe SAS
BAG3 Mutation Associated Dilated Cardiomyopathy
1 trial -
ALXN2420-Acro-201
Alexion Europe SAS
Acromegaly
1 trial -
Alxn1920 placebo product, ALXN1920
Alexion Europe SAS
Primary Mebranous Nephropathy (PMN)
1 trial -
Tarperprumig Placebo, Tarperprumig
Alexion Europe SAS
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
1 trial -
Vialed Saline Placebo, ALXN2030
Alexion Europe SAS
Antibody-Mediated Rejection after Kidney Transplantation
1 trial
Frequently asked questions
How many clinical projects does Alexion Europe SAS have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.